Details for New Drug Application (NDA): 208030

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

NDA 208030 describes FERRIPROX, which is a drug marketed by Chiesi and is included in three NDAs. It is available from two suppliers. There are six patents protecting this drug and one Paragraph IV challenge. Additional details are available on the FERRIPROX profile page.

The generic ingredient in FERRIPROX is deferiprone. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the deferiprone profile page.

Summary for 208030

Tradename:	FERRIPROX
Applicant:	Chiesi
Ingredient:	deferiprone
Patents:	1
Formulation / Manufacturing:	see details

Pharmacology for NDA: 208030

Mechanism of Action	Iron Chelating Activity

Suppliers and Packaging for NDA: 208030

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
FERRIPROX	deferiprone	SOLUTION;ORAL	208030	NDA	Chiesi USA, Inc.	10122-101	10122-101-50	500 mL in 1 BOTTLE, PLASTIC (10122-101-50)
FERRIPROX	deferiprone	SOLUTION;ORAL	208030	NDA	ApoPharma USA, Inc.	52609-4502	52609-4502-7	500 mL in 1 BOTTLE, PLASTIC (52609-4502-7)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;ORAL			Strength	100MG/ML
Approval Date:	Sep 9, 2015	TE:		RLD:	Yes
Regulatory Exclusivity Expiration:	Apr 30, 2024
Regulatory Exclusivity Use:	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
Patent:	See Plans and Pricing	Patent Expiration:	Oct 26, 2029	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION;ORAL			Strength	80MG/ML
Approval Date:	Apr 20, 2018	TE:		RLD:	Yes
Regulatory Exclusivity Expiration:	Apr 30, 2024
Regulatory Exclusivity Use:	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS

Expired US Patents for NDA 208030

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chiesi	FERRIPROX	deferiprone	SOLUTION;ORAL	208030-002	Apr 20, 2018	See Plans and Pricing	See Plans and Pricing
Chiesi	FERRIPROX	deferiprone	SOLUTION;ORAL	208030-001	Sep 9, 2015	See Plans and Pricing	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.